In yesterday’s Wall Street session, Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) shares traded at $0.26, up 8.06% from the previous session.
As of this writing, 2 analysts cover Pieris Pharmaceuticals Inc. (NASDAQ:PIRS). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $7.00 and a low of $7.00, we find $7.00. Given the previous closing price of $0.24, this indicates a potential upside of 2816.67 percent. PIRS stock price is now -25.26% away from the 50-day moving average and -72.16% away from the 200-day moving average. The market capitalization of the company currently stands at $20.30M.
There are 1 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $7.00 as their price target over the next twelve months.
With the price target maintained at $5, Robert W. Baird recently Upgraded its rating from Neutral to Outperform for Pieris Pharmaceuticals Inc. (NASDAQ: PIRS).
In other news, KIRITSY CHRISTOPHER P, Director bought 10,000 shares of the company’s stock on May 25. The stock was bought for $8,500 at an average price of $0.85. Upon completion of the transaction, the Director now directly owns 20,000 shares in the company, valued at $5200.0. A total of 14.98% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PIRS stock. A new stake in Pieris Pharmaceuticals Inc. shares was purchased by SILVERARC CAPITAL MANAGEMENT, LLC during the first quarter worth $250,000. CM MANAGEMENT, LLC invested $143,000 in shares of PIRS during the first quarter. In the first quarter, BAADER BANK AKTIENGESELLSCHAFT acquired a new stake in Pieris Pharmaceuticals Inc. valued at approximately $3,000. TWO SIGMA SECURITIES, LLC acquired a new stake in PIRS for approximately $3,000. ROYAL BANK OF CANADA purchased a new stake in PIRS valued at around $1,000 in the second quarter. In total, there are 70 active investors with 55.40% ownership of the company’s stock.
Thursday morning saw Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) opened at $0.2529. During the past 12 months, Pieris Pharmaceuticals Inc. has had a low of $0.16 and a high of $1.97. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.90, and a quick ratio of 1.90. The fifty day moving average price for PIRS is $0.3353 and a two-hundred day moving average price translates $0.9298 for the stock.
The latest earnings results from Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at $0.05, beating analysts’ expectations of -$0.16 by 0.21. This compares to -$0.14 EPS in the same period last year. The net profit margin was -81.40% and return on equity was -90.40% for PIRS. The company reported revenue of $20.05 million for the quarter, compared to $3.7 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 442.32 percent. For the current quarter, analysts expect PIRS to generate $7.74M in revenue.
Pieris Pharmaceuticals Inc.(PIRS) Company Profile
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
